Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.49% | 24.28% | -162.70% | 27.22% | -29.25% |
| Total Depreciation and Amortization | 49.72% | 23.76% | 15.56% | 13.72% | 19.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.30% | -105.41% | 7,775.08% | -95.09% | 29.97% |
| Change in Net Operating Assets | -50.85% | 1,310.32% | -113.61% | 215.27% | -108.62% |
| Cash from Operations | -29.04% | -4.31% | -115.85% | 45.80% | -38.52% |
| Capital Expenditure | 47.06% | -69.17% | -220.03% | 63.66% | 1.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | 99.78% | -41,313.09% | -220.03% | 63.66% | 1.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 4,500.11% | -97.98% | 30,716.47% | -44.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.10% | 4,500.11% | -97.98% | 30,716.47% | -44.22% |
| Foreign Exchange rate Adjustments | 36.64% | -1,422.12% | 124.69% | -124.84% | 478.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.47% | -162.79% | -112.13% | 999.90% | -36.17% |